Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EphA2 monoclonal antibody
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intranasal, Intravenous
01
Overview
EphA2 monoclonal antibody refers to a class of monoclonal antibodies designed to target and bind to Ephrin type-A receptor 2 (EphA2), a receptor tyrosine kinase that is overexpressed in various cancers and implicated in vascular permeability, inflammation, and tissue injury. In preclinical models, EphA2 monoclonal antibodies have been investigated for their potential to block EphA2/ephrinA1 signaling, thereby preserving alveolar-endothelial barrier integrity, reducing inflammatory cytokine activation, and mitigating hyperoxia-induced acute lung injury (HALI) and lipopolysaccharide (LPS)-induced acute lung injury. In oncology, anti-EphA2 antibodies (such as DS-8895a) have been evaluated in clinical trials to inhibit tumor growth and metastasis through mechanisms like antibody-dependent cellular cytotoxicity (ADCC).
- Other names
- EphA2 antibodyEphA-2 antibodyEphA 2 antibodyEphA2 mAbEphA-2 mAbEphA 2 mAbanti-EphA2 mAbanti-EphA-2 mAbanti-EphA 2 mAbanti-EphA2 monoclonal antibodyanti-EphA-2 monoclonal antibodyanti-EphA 2 monoclonal antibody
02
Targets
EPHA2 (Ephrin type-A receptor 2)
Beyond the preview
Go deeper on EphA2 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EphA2 monoclonal antibody.